Dose-Finding Based on Efficacy-Toxicity Trade-Offs

DOI10.1111/J.0006-341X.2004.00218.XzbMATH Open1274.62883WikidataQ45038149 ScholiaQ45038149MaRDI QIDQ70261FDOQ70261

Authors: Peter F. Thall, John D. Cook, Peter F. Thall, John D. Cook 

Publication date: 27 August 2004

Published in: Biometrics (Search for Journal in Brave)

Recommendations

• Optimal dose‐finding for efficacy–safety models
• Adaptive designs for dose-finding based on efficacy-toxicity response
• Optimal designs for dose-finding experiments in toxicity studies
• scientific article; zbMATH DE number 5257966
• Target toxicity design for phase I dose-finding
• Performance Measures in Dose‐Finding Experiments

Mathematics Subject Classification ID

Bayesian inference (62F15) Applications of statistics to biology and medical sciences; meta analysis (62P10)

Cites Work

• Dose-finding designs for HIV studies
• Title not available (Why is that?)
• Spherical-Radial Integration Rules for Bayesian Computation
• Title not available (Why is that?)
• Selecting Therapeutic Strategies Based on Efficacy and Death in Multicourse Clinical Trials
• A Strategy for Dose-Finding and Safety Monitoring Based on Efficacy and Adverse Outcomes in Phase I/II Clinical Trials
• Approaches for Optimal Sequential Decision Analysis in Clinical Trials
• A Simplex Method for Function Minimization
• Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer

Cited In (72)

• Dose-finding designs for HIV studies
• Flexible link continual reassessment methods for trivariate binary outcome phase I/II trials
• Designs for phase II trials with trade-of between efficacy and toxicity
• A Three-Stage Bayesian Adaptive Phase I/II Design and Simulation Studies
• A conversation with Nancy Flournoy
• Bayesian models and decision algorithms for complex early phase clinical trials
• Dose-finding based on feasibility and toxicity in T-cell infusion trials
• Information in a two-stage adaptive optimal design
• Some geometric methods for constructing decision criteria based on two-dimensional parame\-ters
• Treatment Comparisons Based on Two‐Dimensional Safety and Efficacy Alternatives in Oncology Trials
• A Bayesian adaptive design for dual-agent phase I-II oncology trials integrating efficacy data across stages
• TITE-gBOIN-ET: time-to-event generalized Bayesian optimal interval design to accelerate dose-finding accounting for ordinal graded efficacy and toxicity outcomes
• Incorporating individual and collective ethics into phase I cancer trial designs
• Optimizing the concentration and bolus of a drug delivered by continuous infusion
• BIPSE: a biomarker-based phase I/II design for immunotherapy trials with progression-free survival endpoint
• Optimal drug dosage subject to constraints
• Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials
• Adaptive designs for dose-finding based on efficacy-toxicity response
• Title not available (Why is that?)
• Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios
• Time-to-event continual reassessment method incorporating treatment cycle information with application to an oncology phase I trial
• A New Dose‐Finding Design for Bivariate Outcomes
• A bargaining approach for resolving the tradeoff between beneficial and harmful drug responses
• Coherence principles in dose-finding studies
• gBOIN‐ET: The generalized Bayesian optimal interval design for optimal dose‐finding accounting for ordinal graded efficacy and toxicity in early clinical trials
• A new characterization of Elfving's method for high dimensional computation
• Pharmacokinetically guided optimum adaptive dose selection in early phase clinical trials
• A Bayesian adaptive dose-finding algorithm for balancing individual- and population-level ethics in Phase I clinical trials
• A semiparametric Bayesian approach to population finding with time‐to‐event and toxicity data in a randomized clinical trial
• A Strategy for Dose-Finding and Safety Monitoring Based on Efficacy and Adverse Outcomes in Phase I/II Clinical Trials
• Novel Bayesian Adaptive Designs and Their Applications in Cancer Clinical Trials
• Title not available (Why is that?)
• Adaptive Bayesian phase I clinical trial designs for estimating the maximum tolerated doses for two drugs while fully utilizing all toxicity information
• Bayesian phase I/II adaptively randomized oncology trials with combined drugs
• A Bayesian Phase I/II Trial Design for Immunotherapy
• A Bayesian adaptive design for addressing correlated late-onset outcomes in phase I/II randomized trials of drug combinations in oncology
• Correlated endpoints: simulation, modeling, and extreme correlations
• Bayesian phase II adaptive randomization by jointly modeling time-to-event efficacy and binary toxicity
• Efficiency of bridging between related dose finding studies
• Rejoinder
• A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes
• Using joint utilities of the times to response and toxicity to adaptively optimize schedule-dose regimes
• escalation
• Adaptive designs for selecting drug combinations based on efficacy-toxicity response
• Design efficiency in dose finding studies
• Simple benchmark for complex dose finding studies
• Optimal design to discriminate between rival copula models for a bivariate binary response
• A hybrid geometric phase II/III clinical trial design based on treatment failure time and toxicity
• trialr
• A multi-armed Bayesian ordinal outcome utility-based sequential trial with a pairwise null clustering prior
• Patient‐Specific Dose Finding Based on Bivariate Outcomes and Covariates
• Sequential methods in multi-arm clinical trials
• A review of phase 2-3 clinical trial designs
• A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies
• TITE-BOIN12: a Bayesian phase I/II trial design to find the optimal biological dose with late-onset toxicity and efficacy
• DROID: dose-ranging approach to optimizing dose in oncology drug development
• A Bayesian design for phase I cancer therapeutic vaccine trials
• A seamless phase II/III design with dose optimization for oncology drug development
• REDOMA: Bayesian random-effects dose-optimization meta-analysis using spike-and-slab priors
• Change-point joint model for identification of plateau of activity in early phase trials
• A Bayesian phase I/II platform design for co-developing drug combination therapies for multiple indications
• Combined criteria for dose optimisation in early phase clinical trials
• Comparative review of novel model-assisted designs for phase I/II clinical trials
• A phase I--II design based on periodic and continuous monitoring of disease status and the times to toxicity and death
• Hybrid design evaluating new biomarkers when there is an existing screening test
• A Bayesian adaptive phase i/II platform trial design for pediatric immunotherapy trials
• Bayesian modeling of a bivariate toxicity outcome for early phase oncology trials evaluating dose regimens
• uTPI: a utility-based toxicity probability interval design for phase I/II dose-finding trials
• Seamless phase I/II design for novel anticancer agents with competing disease progression
• Subgroup-specific dose finding for phase I-II trials using Bayesian clustering
• Utility based approach in individualized optimal dose selection using machine learning methods
• Group sequential designs for clinical trials with bivariate endpoints

This page was built for publication: Dose-Finding Based on Efficacy-Toxicity Trade-Offs

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q70261)